Ring Christine reported option exercise involving 5,786 shares of Nurix Therapeutics, Inc. at $8.72 for $50.5k on Oct 2, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Legal Officer
Chief Legal Officer
Filed Oct 2, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$50,453.92Shares × reported price
Shares traded
5,786Common Stock
Price per share
$8.72Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
14,896Direct
Trade date
Oct 2, 2026Option exercise
Filed
Oct 2, 2026, 5:21 PM ET0-day reporting delay
Accession
0001817199-26-000032Code M · Transaction 235473
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Oct 2, 2026Sell5,786$23.19−$134,148.99Trade 235474
Oct 2, 2026Option exercise5,786$0.00$0Trade 235475
3 transaction rows in this filing. Joint filers share the same rows.

NRIX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NRIX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +12%1w ago +0.1%1d ago +1.5%
Returns since7d −2.8%30d +17%90d180d1y

Footnotes in full

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.